Symbols / ANIK Stock $14.85 +19.28% Anika Therapeutics, Inc.

Healthcare • Drug Manufacturers - Specialty & Generic • United States • NMS
ANIK (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
CEO —
Exch · Country NMS · United States
Market Cap 197.59M
Enterprise Value 151.23M
Income -11.08M
Sales 116.26M
FCF (ttm) 8.30M
Book/sh 10.33
Cash/sh 3.03
Employees 235
Insider 10d —
IPO May 03, 1993
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E 37.12
PEG 4.96
P/S 1.70
P/B 1.44
P/C —
EV/EBITDA -22.05
EV/Sales 1.30
Quick Ratio 3.19
Current Ratio 4.46
Debt/Eq 17.77
LT Debt/Eq —
EPS (ttm) -0.79
EPS next Y 0.40
EPS Growth —
Revenue Growth 13.20%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-07-29
Earnings (prior) 2026-04-29
ROA -4.14%
ROE -7.85%
ROIC —
Gross Margin 58.59%
Oper. Margin -18.53%
Profit Margin -9.52%
Shs Outstand 13.31M
Shs Float 11.46M
Insider Own 5.93%
Instit Own 93.96%
Short Float 5.72%
Short Ratio 4.97
Short Interest 644.57K
52W High 16.24
vs 52W High -8.56%
52W Low 7.87
vs 52W Low 88.69%
Beta 0.28
Impl. Vol. —
Rel Volume 1.60
Avg Volume 145.25K
Volume 232.47K
Target (mean) $17.50
Tgt Median $17.50
Tgt Low $17.00
Tgt High $18.00
# Analysts 2
Recom Strong_buy
Prev Close $12.45
Price $14.85
Change 19.28%
About

Anika Therapeutics, Inc., a joint preservation company, focuses on early intervention orthopedics in the United States, Europe, and internationally. The company offers osteoarthritis (OA) pain management products and services, such as Monovisc and Orthovisc, which are single- and multi-injection, HA viscosupplement products indicated for pain relief from OA conditions, as well as Cingal, a non-opioid, single-injection OA pain management product; regenerative solutions, including an HA-based scaffold with bone and tendon fixation components and arthroscopic delivery instruments; Hyalofast, a resorbable scaffold used for single stage cartilage regeneration; and Tactoset injectable bone substitute, an HA-enhanced injectable bone repair therapy designed to treat insufficiency fractures and augment hardware fixation. It also provides Integrity, an HA-based scaffold with bone and tendon fixation components and arthroscopic delivery instruments; non-orthopedic products, including Hyvisc, a high molecular weight injectable HA veterinary product for the treatment of joint dysfunction in horses due to non-infectious synovitis associated with equine OA; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and ophthalmic products; and Anikavisc and Nuvisc high molecular weight HA products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$17.50
Mean price target
2. Current target
$14.85
Latest analyst target
3. DCF / Fair value
$11.23
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$14.85
Low
$17.00
High
$18.00
Mean
$17.50

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-02-27 main Barrington Research Outperform → Outperform $17
2026-01-09 main Barrington Research Outperform → Outperform $16
2025-11-06 main Barrington Research Outperform → Outperform $16
2025-09-23 main Barrington Research Outperform → Outperform $15
2025-07-31 main Barrington Research Outperform → Outperform $15
2025-05-12 main Barrington Research Outperform → Outperform $19
2025-03-13 main Barrington Research Outperform → Outperform $20
2024-11-01 main Barrington Research Outperform → Outperform $25
2024-10-22 main Barrington Research Outperform → Outperform $37
2024-08-09 main Barrington Research Outperform → Outperform $37
2024-05-29 reit Stephens & Co. Equal-Weight → Equal-Weight $24
2024-05-09 main Barrington Research Outperform → Outperform $37
2024-03-14 main Barrington Research Outperform → Outperform $37
2024-03-14 reit Stephens & Co. Equal-Weight → Equal-Weight $22
2024-01-03 main Barrington Research Outperform → Outperform $29
2023-11-03 main Barrington Research Outperform → Outperform $28
2023-08-14 up Barrington Research Market Perform → Outperform $24
2023-08-10 main Stephens & Co. Equal-Weight → Equal-Weight $23
2023-05-31 reit Stephens & Co. Equal-Weight → Equal-Weight $28
2023-04-14 reit Stephens & Co. — → Equal-Weight $28
News
RSS: Latest ANIK news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-30 GRIFFIN STEPHEN D Chief Executive Officer — 12,200 $12.29 $149,881
2026-03-13 BLANCHARD CHERYL R Director — 24,520 $0.00 $0
2026-03-13 BLANCHARD CHERYL R Director — 49,650 — —
2026-03-13 MCLEOD IAN W Officer and Treasurer — 1,161 $0.00 $0
2026-03-13 MCLEOD IAN W Officer and Treasurer — 6,432 — —
2026-03-13 COLLERAN DAVID B J.D. General Counsel — 4,694 $0.00 $0
2026-03-13 COLLERAN DAVID B J.D. General Counsel — 15,837 — —
2026-03-13 GRIFFIN STEPHEN D Chief Executive Officer — 6,412 $0.00 $0
2026-03-13 GRIFFIN STEPHEN D Chief Executive Officer — 12,824 — —
2026-03-09 BLANCHARD CHERYL R Director — 20,001 — —
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
112.82
-5.91%
119.91
-0.73%
120.79
+6.12%
113.83
Operating Revenue
112.82
-5.91%
119.91
-0.73%
120.79
+6.12%
113.83
Cost Of Revenue
49.01
+11.62%
43.91
+14.76%
38.26
-5.78%
40.61
Reconciled Cost Of Revenue
49.01
+11.62%
43.91
+14.76%
38.26
-5.78%
40.61
Gross Profit
63.81
-16.04%
76.00
-7.92%
82.53
+12.72%
73.22
Operating Expense
74.86
-7.70%
81.10
-0.72%
81.69
+17.45%
69.55
Research And Development
25.77
+0.88%
25.54
+17.37%
21.76
+18.79%
18.32
Selling General And Administration
49.09
-11.64%
55.55
-7.29%
59.92
+16.97%
51.23
Total Expenses
123.87
-0.91%
125.01
+4.22%
119.95
+8.89%
110.16
Operating Income
-11.05
-116.64%
-5.10
-704.38%
0.84
-77.00%
3.67
Total Operating Income As Reported
-11.05
-116.64%
-5.10
-704.38%
0.84
-77.00%
3.67
EBITDA
-5.32
-276.23%
3.02
-79.95%
15.06
-17.05%
18.16
Normalized EBITDA
-5.32
-276.23%
3.02
-79.95%
15.06
-17.05%
18.16
Reconciled Depreciation
5.73
-29.45%
8.12
-42.88%
14.22
-1.86%
14.49
EBIT
-11.05
-116.64%
-5.10
-704.38%
0.84
-77.00%
3.67
Total Unusual Items
—
—
-62.19
0.00
Total Unusual Items Excluding Goodwill
—
—
-62.19
0.00
Special Income Charges
—
—
-62.19
0.00
Impairment Of Capital Assets
—
—
62.19
0.00
Restructuring And Mergern Acquisition
—
—
0.00
0.00
Net Income
-10.88
+80.70%
-56.38
+31.79%
-82.67
-456.34%
-14.86
Pretax Income
-9.31
-236.72%
-2.76
-187.58%
3.16
-27.01%
4.32
Net Non Operating Interest Income Expense
1.74
-25.37%
2.34
+1.08%
2.31
+253.52%
0.65
Net Interest Income
1.74
-25.37%
2.34
+1.08%
2.31
+253.52%
0.65
Other Income Expense
—
—
-62.19
—
Tax Provision
0.67
-88.92%
6.06
-8.05%
6.59
+210.50%
2.12
Tax Rate For Calcs
0.00
+0.00%
0.00
+0.00%
0.00
+1.45%
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-10.88
+80.70%
-56.38
+31.79%
-82.67
-456.34%
-14.86
Net Income From Continuing Operation Net Minority Interest
-9.98
-13.04%
-8.83
-156.70%
-3.44
-256.32%
2.20
Net Income From Continuing And Discontinued Operation
-10.88
+80.70%
-56.38
+31.79%
-82.67
-456.34%
-14.86
Net Income Continuous Operations
-9.98
-13.04%
-8.83
-156.70%
-3.44
-256.32%
2.20
Net Income Discontinuous Operations
-0.90
+98.11%
-47.56
+39.97%
-79.23
-364.44%
-17.06
Normalized Income
-9.98
-13.04%
-8.83
-156.70%
-3.44
-256.32%
2.20
Net Income Common Stockholders
-10.88
+80.70%
-56.38
+31.79%
-82.67
-456.34%
-14.86
Diluted EPS
-0.76
+80.16%
-3.83
+32.09%
-5.64
-452.94%
-1.02
Basic EPS
-0.76
+80.16%
-3.83
+32.09%
-5.64
-452.94%
-1.02
Basic Average Shares
14.34
-2.60%
14.72
+0.45%
14.66
+0.65%
14.56
Diluted Average Shares
14.34
-2.60%
14.72
+0.45%
14.66
+0.65%
14.56
Diluted NI Availto Com Stockholders
-10.88
+80.70%
-56.38
+31.79%
-82.67
-456.34%
-14.86
Total Other Finance Cost
-1.74
+25.37%
-2.34
-1.08%
-2.31
-253.52%
-0.65
Line Item Trend 2025-12-31 2024-12-31 2023-12-31
Total Assets
190.27
-6.15%
202.74
-25.09%
270.63
Current Assets
103.36
-9.06%
113.65
-30.41%
163.31
Cash Cash Equivalents And Short Term Investments
57.48
+3.33%
55.63
-19.07%
68.74
Cash And Cash Equivalents
57.48
+3.33%
55.63
-19.07%
68.74
Receivables
23.69
+0.41%
23.59
-10.49%
26.36
Accounts Receivable
23.69
+0.41%
23.59
-10.49%
26.36
Gross Accounts Receivable
24.82
+2.03%
24.32
-10.00%
27.03
Allowance For Doubtful Accounts Receivable
-1.13
-54.38%
-0.73
-9.61%
-0.67
Inventory
18.79
-21.09%
23.81
-2.53%
24.43
Raw Materials
—
—
—
Work In Process
—
—
—
Finished Goods
—
—
—
Prepaid Assets
—
—
—
Assets Held For Sale Current
0.00
-100.00%
5.13
-85.88%
36.30
Other Current Assets
3.40
-38.11%
5.49
-26.51%
7.48
Total Non Current Assets
86.91
-2.44%
89.09
-16.99%
107.32
Net PPE
66.26
+2.45%
64.68
-0.49%
65.00
Gross PPE
117.69
+6.06%
110.96
+1.81%
108.99
Accumulated Depreciation
-51.43
-11.11%
-46.28
-5.22%
-43.99
Properties
0.00
0.00
0.00
Machinery Furniture Equipment
1.70
+12.39%
1.51
-12.93%
1.73
Construction In Progress
3.73
-38.25%
6.04
+152.68%
2.39
Other Properties
75.44
+12.47%
67.08
-4.46%
70.21
Leases
36.82
+1.33%
36.34
+4.87%
34.65
Goodwill And Other Intangible Assets
9.70
+0.93%
9.62
-5.24%
10.15
Goodwill
8.05
+13.04%
7.12
-5.89%
7.57
Other Intangible Assets
1.65
-33.73%
2.49
-3.34%
2.58
Non Current Deferred Assets
1.27
+8.33%
1.18
-20.95%
1.49
Non Current Deferred Taxes Assets
1.27
+8.33%
1.18
-20.95%
1.49
Other Non Current Assets
4.03
-47.49%
7.68
-74.97%
30.69
Total Liabilities Net Minority Interest
46.80
-3.99%
48.75
-16.48%
58.37
Current Liabilities
21.91
-6.00%
23.31
-24.96%
31.06
Payables And Accrued Expenses
8.75
-5.15%
9.22
-12.19%
10.51
Payables
6.04
+6.36%
5.68
-23.59%
7.43
Accounts Payable
6.04
+7.55%
5.62
-9.32%
6.19
Current Accrued Expenses
2.71
-23.58%
3.54
+15.40%
3.07
Pensionand Other Post Retirement Benefit Plans Current
11.11
+38.12%
8.04
+1.44%
7.93
Total Tax Payable
0.00
-100.00%
0.06
-94.92%
1.24
Income Tax Payable
0.00
-100.00%
0.06
-94.92%
1.24
Current Debt And Capital Lease Obligation
2.05
+6.99%
1.92
+4.98%
1.83
Current Capital Lease Obligation
2.05
+6.99%
1.92
+4.98%
1.83
Other Current Liabilities
—
4.12
-61.83%
10.80
Total Non Current Liabilities Net Minority Interest
24.90
-2.15%
25.45
-6.82%
27.31
Liabilities Heldfor Sale Non Current
0.00
-100.00%
0.66
-33.37%
0.99
Long Term Debt And Capital Lease Obligation
24.20
+0.76%
24.01
-7.34%
25.91
Long Term Capital Lease Obligation
24.20
+0.76%
24.01
-7.34%
25.91
Non Current Deferred Liabilities
—
—
0.00
Non Current Deferred Taxes Liabilities
—
—
0.00
Other Non Current Liabilities
0.70
-9.20%
0.77
+91.09%
0.40
Stockholders Equity
143.47
-6.83%
153.99
-27.45%
212.26
Common Stock Equity
143.47
-6.83%
153.99
-27.45%
212.26
Capital Stock
0.14
-3.47%
0.14
-2.04%
0.15
Common Stock
0.14
-3.47%
0.14
-2.04%
0.15
Preferred Stock
0.00
0.00
0.00
Share Issued
15.38
+2.50%
15.01
+1.09%
14.85
Ordinary Shares Number
13.89
-3.66%
14.42
-1.66%
14.66
Treasury Shares Number
1.50
+151.85%
0.59
+215.96%
0.19
Additional Paid In Capital
87.50
-1.64%
88.96
-1.16%
90.01
Retained Earnings
60.79
-15.18%
71.67
-44.03%
128.05
Gains Losses Not Affecting Retained Earnings
-4.96
+26.89%
-6.78
-14.13%
-5.94
Other Equity Adjustments
-4.96
+26.89%
-6.78
-14.13%
-5.94
Total Equity Gross Minority Interest
143.47
-6.83%
153.99
-27.45%
212.26
Total Capitalization
143.47
-6.83%
153.99
-27.45%
212.26
Working Capital
81.45
-9.85%
90.35
-31.69%
132.25
Invested Capital
143.47
-6.83%
153.99
-27.45%
212.26
Total Debt
26.25
+1.22%
25.93
-6.52%
27.74
Capital Lease Obligations
26.25
+1.22%
25.93
-6.52%
27.74
Net Tangible Assets
133.76
-7.35%
144.37
-28.57%
202.12
Tangible Book Value
133.76
-7.35%
144.37
-28.57%
202.12
Non Current Note Receivables
5.64
-5.04%
5.93
0.00
Other Inventories
—
—
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
11.19
+107.07%
5.40
+402.18%
-1.79
-140.55%
4.41
Cash Flow From Continuing Operating Activities
11.19
+107.07%
5.40
+402.18%
-1.79
-140.55%
4.41
Net Income From Continuing Operations
-10.88
+80.70%
-56.38
+31.79%
-82.67
-456.34%
-14.86
Depreciation Amortization Depletion
5.73
-29.45%
8.12
-42.88%
14.22
-1.86%
14.49
Depreciation
5.37
-21.96%
6.88
+6.99%
6.43
-4.03%
6.70
Amortization Cash Flow
0.36
-71.14%
1.24
-84.11%
7.78
+0.00%
7.78
Depreciation And Amortization
5.73
-29.45%
8.12
-42.88%
14.22
-1.86%
14.49
Amortization Of Intangibles
0.36
-71.14%
1.24
-84.11%
7.78
+0.00%
7.78
Other Non Cash Items
1.17
-45.81%
2.15
-3.63%
2.23
+20.59%
1.85
Stock Based Compensation
10.08
-23.20%
13.13
-13.86%
15.24
+6.48%
14.31
Provisionand Write Offof Assets
6.09
-86.74%
45.89
+1199.72%
3.53
-38.13%
5.71
Asset Impairment Charge
0.00
-100.00%
2.46
-96.04%
62.19
0.00
Deferred Tax
-0.01
-102.69%
0.26
+104.11%
-6.33
-20.06%
-5.27
Deferred Income Tax
-0.01
-102.69%
0.26
+104.11%
-6.33
-20.06%
-5.27
Operating Gains Losses
-0.17
-105.80%
2.86
+49.40%
1.92
—
Gain Loss On Sale Of PPE
-0.17
-105.80%
2.86
+49.40%
1.92
0.00
Change In Working Capital
-0.82
+93.71%
-13.09
-7.99%
-12.12
-2.55%
-11.82
Change In Receivables
0.41
-87.88%
3.37
+357.93%
-1.30
+76.82%
-5.63
Changes In Account Receivables
0.41
-87.88%
3.37
+357.93%
-1.30
+76.82%
-5.63
Change In Inventory
0.03
+100.32%
-9.42
+17.30%
-11.40
-65.81%
-6.87
Change In Prepaid Assets
2.33
+317.03%
0.56
-0.36%
0.56
+170.71%
-0.79
Change In Payables And Accrued Expense
-1.46
+76.39%
-6.17
-477.21%
1.64
+7.56%
1.52
Change In Accrued Expense
-1.50
+59.12%
-3.67
-322.63%
1.65
+472.01%
-0.44
Change In Payable
0.04
+101.68%
-2.51
-22681.82%
-0.01
-100.56%
1.97
Change In Account Payable
0.04
+101.68%
-2.51
-22681.82%
-0.01
-100.56%
1.97
Change In Other Working Capital
-0.13
-120.15%
0.67
+25.47%
0.53
-63.12%
1.44
Change In Other Current Liabilities
-2.00
+4.13%
-2.08
+3.12%
-2.15
-44.71%
-1.49
Investing Cash Flow
-0.40
+95.19%
-8.33
-53.57%
-5.43
+27.50%
-7.49
Cash Flow From Continuing Investing Activities
-0.40
+95.19%
-8.33
-53.57%
-5.43
+27.50%
-7.49
Net PPE Purchase And Sale
-6.83
+11.74%
-7.73
-42.51%
-5.43
+27.50%
-7.49
Purchase Of PPE
-6.83
+11.74%
-7.73
-42.51%
-5.43
+27.50%
-7.49
Capital Expenditure
-6.83
+18.09%
-8.33
-53.57%
-5.43
+27.50%
-7.49
Net Investment Purchase And Sale
—
—
0.00
0.00
Purchase Of Investment
—
—
—
0.00
Sale Of Investment
—
—
0.00
0.00
Net Business Purchase And Sale
—
—
0.00
0.00
Purchase Of Business
—
—
0.00
0.00
Net Intangibles Purchase And Sale
0.60
+200.00%
-0.60
0.00
0.00
Purchase Of Intangibles
0.00
+100.00%
-0.60
0.00
0.00
Net Other Investing Changes
5.83
—
—
—
Financing Cash Flow
-10.55
+17.11%
-12.73
-101.28%
-6.32
-30.34%
-4.85
Cash Flow From Continuing Financing Activities
-10.55
+17.11%
-12.73
-101.28%
-6.32
-30.34%
-4.85
Net Issuance Payments Of Debt
—
0.00
0.00
+100.00%
-0.28
Issuance Of Debt
—
—
—
0.00
Repayment Of Debt
—
0.00
0.00
+100.00%
-0.28
Long Term Debt Issuance
—
—
—
0.00
Long Term Debt Payments
—
0.00
0.00
+100.00%
-0.28
Net Long Term Debt Issuance
—
0.00
0.00
+100.00%
-0.28
Net Common Stock Issuance
-9.48
+13.09%
-10.91
-118.28%
-5.00
0.00
Common Stock Payments
-9.48
+13.09%
-10.91
-118.28%
-5.00
0.00
Repurchase Of Capital Stock
-9.48
+13.09%
-10.91
-118.28%
-5.00
0.00
Proceeds From Stock Option Exercised
0.50
-36.22%
0.78
-5.31%
0.83
+21.59%
0.68
Net Other Financing Charges
-1.57
+39.75%
-2.60
-20.77%
-2.15
+59.00%
-5.25
Changes In Cash
0.24
+101.51%
-15.66
-15.67%
-13.54
-70.75%
-7.93
Effect Of Exchange Rate Changes
0.09
+279.17%
-0.05
-160.76%
0.08
+160.77%
-0.13
Beginning Cash Position
57.16
-21.56%
72.87
-15.59%
86.33
-8.54%
94.39
End Cash Position
57.48
+0.56%
57.16
-21.56%
72.87
-15.59%
86.33
Free Cash Flow
4.36
+248.82%
-2.93
+59.38%
-7.21
-134.48%
-3.08
Income Tax Paid Supplemental Data
1.08
-73.05%
3.99
+28.10%
3.12
+2840.57%
0.11
Sale Of Intangibles
0.60
0.00
0.00
—
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category